AP3 Rec'd PCT/PTO 15 MAY 200



PTO/SB/21 (02-04)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Provide Peduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Under Paperwork Reduction Act of 1995, no.				EPARTMENT OF COMMERCE		
TRADE NO.	Application Number	10/551,874	it discis	VS & Valley Only Control Humber.		
TRANSMITTAL	Filing Date	September 30, 2005				
FORM	First Named Inventor	RUSSWURM				
(to be used for all correspondence after initial filing	Art Unit					
	Examiner Name					
Total Number of Pages in This Submission	Attorney Docket Number	9740-1				
	ENCLOSURES (Check all that	apply)				
Fee Transmittal Form Fee Attached Amendment/Reply After Final Affidavits/declaration(s) Extension of Time Request Express Abandonment Request Information Disclosure Statement Certified Copy of Priority Document(s)	Drawing(s) Licensing-related Papers Petition Petition to Convert to a Provisional Application Power of Attorney, Revocation Change of Correspondence Addre Terminal Disclaimer Request for Refund CD, Number of CD(s) Remarks	to Te Appe of Ap Appe (Appe (Appe) Prop Statu Othe Ident	echnological Conopeals and Conopeal Notice Individual Notice Individual Letter Enclositify below reign R	osure(s) (please ow): References; and		
Response to Missing Parts/ Incomplete Application Response to Missing Parts under 37 CFR 1.52 or 1.53	he Commissioner is authorized to charg		es to De	eposit Account No. 50-0951		
Firm Nicholas A. Zachariades	RE OF AFFLICANT, ATTORIN	LI, OR AGENT				
or Reg. No. 56,712						
Signature National	•					
Date May 10, 2006						
CER	TIFICATE OF TRANSMISSION	/MAILING				
I hereby certify that this correspondence is being sufficient postage as first class mail in an envelopment the date shown below.	g facsimile transmitted to the USPTO or	deposited with the U				
Typed or printed name Nicholas A. Zacharia	des, Reg. No. 56,712					
Signature Nath	-		Date	May 10, 2006)		

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

THE UNITED STATES PATENT AND TRADEMARK OFFICE

e: Application of: RUSSWURM et al.

Application No.:

10/551,874

Examiner:

Date Filed:

September 30, 2005

Group:

For:

METHOD FOR RECOGNIZING ACUTE GENERALIZED INFLAMMATORY CONDITIONS (SIRS), SEPSIS, SEPSIS-LIKE CONDITIONS AND SYSTEMATIC

INFECTIONS

Certificate of Transmission/Mailing

Nicholas A. Zachariades, Registration No. 56,712

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir/Madam:

In accordance with the duty of disclosure under 37 C.F.R. §1.56, Applicant hereby notifies the U.S. Patent Office of the documents listed on the attached Form PTO/SB/08B.

Applicant certifies that each item of information contained in the Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Supplemental Information Disclosure Statement. Copies of the foreign references are enclosed.

Submission of the listed documents is not intended as an admission that such documents constitute prior art against the present application. Applicant does not waive any right to take any action that would be appropriate to antedate or otherwise remove the listed documents as competent references against the present application. Applicant submits that the present invention is patentable over the cited references. No fee is believed due however, the Commissioner is authorized to charge any fee deficiencies to Deposit Account No. 50-0951.

Respectfully submitted,

AKERMAN SENTERFITT

Date:

May 10, 2006

Nicholas A. Zachariades Registration No. 56,712

P.O. Box 3188

West Palm Beach, FL 33402-3188

Tel: 561-653-5000 Fax: 561-659-6313

Docket No. 9740-1

MAY 1 5 2006 8

PTO/SB/08B (07-05)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

e Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		Complete if Known			
Oubsitu	te for form 144307 TO			Application Number	10/551,874
INF	ORMATION	DIS	CLOSURE	Filing Date	September 30, 2005
STATEMENT BY APPLICANT		First Named Inventor	RUSSWURM		
(Use as many sheets as necessary)				Art Unit	
			ecessary)	Examiner Name	
Sheet	1	of	1	Attorney Docket Number	9740-1

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Database NETAFFX; 15 March 2006 http://www.affymetrix.com/analysis/netaffx/probematch/probe_match.affx?netaffx=netaffx4_annot	
		Ray et al. "Peptide nucleic acid (PNA): its medical and biotechnical applications and promise for the future", 2000, Medical and Biotechnical Applications of PNA, 14:1041-1060	
		Jansen et al. "Antisense therapy for cancer - the time of truth", 2002, The Lancet Oncology, 3:672-683	
		Galderisi et al. "Antisense Oligonucleotides as Therapeutic Agents", 1999, Journal of Cellular Physiology, 181:251-257	
		Riesewijk et al. "Gene expression profiling of human endometrial receptivity on days LH+2 versus LH+7 by microarray technology", 2003, 9(5):253-264	
		Liu et al. "Gene expression profiles in human nasal polyp tissues studied by means of DNA microarray", 2004, 114(4):783-790	
		Tsukahara et al. "Gene Expression in Human Neutrophils During Activation and Priming by Bacterial Lipopolysaccharide", 2003, Journal of Cellular Biochemistry, 89:848-861	

Examiner	Date	
Signature	 Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.